Adverse Drug Event, Bone and Joint Infection, Osteomyelitis
Conditions
Keywords
bone and joint infection, osteomyelitis, mandibular, denosumab
Brief summary
The aim of this study is to adescription of mandibular osteomylitis in patients having had a treatment by DENOSUMAB. Indeed, one of the adverse effect ot this molecule is to induce mandibular infection.
Interventions
OTHERmandibular osteomylitis
Sponsors
Hospices Civils de Lyon
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* patients having a mandibular osteomylelitis due to DENOSUMAB
Exclusion criteria
* none
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of mandibular osteomyelitis | Entire description can be made at the outcome which is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption | description of mandibular osteomyelitis |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of antibiotics | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption | Description of the duration and strategies of antibiotic treatments used (double-agent therapy, monotherapy) |
| Rate of Treatment Failure | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption | Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin. Analyse of risk factor. |
| management of mandibular osteomyelitis by medical team | all data are available at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption | description of medical and surgical strategies : data availables in consultation report |
Countries
France
Outcome results
None listed